Abeona Therapeutics announces strategic review
Abeona Therapeutics announced that it has retained Jefferies LLC as its financial advisor to assist with the review of strategic options focused on advancing the Company's mission and maximizing stakeholder value. In response to interest, Abeona has initiated a process to explore a broad range of strategic alternatives, including, but not limited to the partnering of its various clinical and pre-clinical programs, or a sale or merger of the Company, in an effort to unlock the potential of those assets. "With four clinical stage programs, a broad pre-clinical pipeline, GMP manufacturing facilities, and a talented team, Abeona remains committed to advancing the promise of genetic medicine," said Joao Siffert, M.D., Chief Executive Officer. "Given our expertise in gene and cell therapy, we believe we are well positioned to explore a variety of opportunities, pursue strategic partnerships and alliances, improve our capital structure, and accelerate development of candidates towards commercialization."